Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate a new future after a planned merger with cancer imaging company Kuva Labs fell apart.
Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate a new future after a planned merger with cancer imaging company Kuva Labs fell apart.
